Buying in12 May 2020 23:09
https://www.lse.co.uk/rns/FARN/faron-pharma-oy-grant-of-options-lj1p9e3nb2r2ayv.html
Grant of options
TURKU - FINLAND, 1 July 2019 - Faron (LON: FARN), the clinical stage biopharmaceutical company, announces that the Board of Faron has on 1 July 2019 confirmed the grant of 40,000 D options over ordinary shares in the Company ("Options") under the Faron 2015 Option Plan to Mr. Toni Hänninen, who was appointed as Faron's new CFO from 1 June 2019. The Options have been allocated under the Faron 2015 Option Plan and are exercisable between 8 October 2018 and 30 September 2021 at an exercise price of 109 euro cents per share, as announced on 22 May 2019. The exercise price is calculated based on the average share price between 1 July and 30 September 2018. The terms of the 2015 Option Plan are as described in the Company's Admission Document (available on the Company's website), as amended at the Company's 2017 annual general meeting, details of which were announced on 16 May 2017